Phenylephrine Bitartrate GRAS/E Status Supported By Bayer Safety Data
This article was originally published in The Tan Sheet
Executive Summary
Phenylephrine bitartrate's favorable safety profile shows the ingredient should be generally recognized as safe and effective, Bayer maintains in a recent citizen petition to FDA
You may also be interested in...
Bayer Bubbles Over Proposed Cough/Cold Monograph Amendment
FDA is proposing to amend the over-the-counter nasal decongestant drugs monograph to include phenylephrine bitartrate (PEB) in effervescent tablets, according to an announcement published in the Federal Register Nov. 2
Nasal Decongestants Monograph Amendment On Sinusitis Claims Planned
FDA is targeting June for a proposed amendment to the cough/cold nasal decongestant monograph regarding sinusitis claims, according to the agency's recently published "unified agenda.
Phenylephrine Bitartrate Foreign Marketing Data Requested By FDA
Bayer should supply foreign marketing data for phenylephrine bitartrate (PEB) to support its request the ingredient be approved for use as a nasal decongestant, FDA said at a "feedback" meeting in Rockville, Md. Feb. 15